Shyamal C Das
Overview
Explore the profile of Shyamal C Das including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Khadka P, Tucker I, Das S
Pharm Res
. 2022 Nov;
40(5):1153-1163.
PMID: 36447019
Purpose: The purpose of this study was to evaluate the in vitro lung dissolution of amorphous and crystalline powder formulations of rifampicin in polyethylene oxide (PEO) and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC), and...
12.
Adhikari B, Sinha S, Lyons N, Pletzer D, Lamont I, Gordon K, et al.
Eur J Pharm Biopharm
. 2022 Oct;
180:260-268.
PMID: 36241076
Co-amorphization of a single drug with amino acid is a technique to improve aerosolization of inhalable spray-dried formulation for inhalation therapy. However, the incorporation of a second drug molecule into...
13.
Khadka P, Dummer J, Hill P, Katare R, Das S
Drug Deliv Transl Res
. 2022 Sep;
13(5):1246-1271.
PMID: 36131190
Inhaled drug delivery is a promising approach to achieving high lung drug concentrations to facilitate efficient treatment of tuberculosis (TB) and to reduce the overall duration of treatment. Rifampicin is...
14.
Adhikari B, Gordon K, Das S
Adv Drug Deliv Rev
. 2022 Aug;
189:114468.
PMID: 35917868
High dose inhaled powders have received increased attention for treating lung infections. These powders can be prepared using techniques such as spray drying, spray-freeze drying, crystallization, and milling. The selected...
15.
Saha T, Sinha S, Harfoot R, Quinones-Mateu M, Das S
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890327
SARS-CoV-2, the causative agent of COVID-19, predominantly affects the respiratory tract. As a consequence, it seems intuitive to develop antiviral agents capable of targeting the virus right on its main...
16.
Saha T, Quinones-Mateu M, Das S
Int J Pharm
. 2022 Jul;
624:122042.
PMID: 35868481
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the COVID-19 pandemic, has outspread at full tilt across the world. Although several effective vaccines continue to be...
17.
Adhikari B, Dummer J, Gordon K, Das S
Expert Opin Drug Deliv
. 2022 Jun;
19(7):795-813.
PMID: 35695722
Introduction: High dose powder inhalation is evolving as an important approach to to treat lung infections. It is important to its identify applications, consider the factors affecting high dose powder...
18.
Adhikari B, Sinha S, Gordon K, Das S
Int J Pharm
. 2022 May;
621:121799.
PMID: 35525472
Pseudomonas aeruginosa infection is common in cystic fibrosis as well as non-cystic fibrosis bronchiectasis. The pathogen presents challenges for treatment due to its adaptive antibiotic-resistance, mainly pertaining to its biofilm-forming...
19.
Adhikari B, Berzins K, Fraser-Miller S, Cavallaro A, Gordon K, Das S
Int J Pharm
. 2022 Jan;
614:121446.
PMID: 34998923
The influence of amino acids, other than leucine, in improving aerosolization of inhalable powders has not been widely explored. This detailed study focused on the use of methionine, another promising...
20.
Saha T, Khadka P, Das S
Germs
. 2021 Nov;
11(3):408-417.
PMID: 34722363
During the COVID-19 pandemic, the use of alcohol-based hand sanitizers (ABHS) increased worldwide among the public as well as the health care workers in pursuit to prevent the spread of...